sutimlimab sold brand name enjaymo monoclonal antibody used treat adults cold agglutinin disease given intravenous sutimlimab prevents complementenhanced activation autoimmune human b cells common side effects include headache high blood pressure urinary tract infection infection structures carry urine upper respiratory tract infection nose throat infection nasopharyngitis inflammation nose throat nausea abdominal pain infusionrelated reactions cyanosis bluish discoloration hands feet response cold drug developed bioverativ sanofi sutimlimab approved medical use united states february european union november us food drug administration fda considers firstinclass sutimlimab indicated decrease need red blood cell transfusion due hemolysis red blood cell destruction adults cold agglutinin disease common side effects include respiratory tract infection viral infection diarrhea dyspepsia indigestion cough arthralgia joint stiffness arthritis swelling lower legs two phase studies patients experienced infusionrelated reactions including shortness breath rapid heartbeat nausea flushing headache hypotension chest discomfort pruritis rash injection site reaction sutimlimab targets enzyme inhibits enzymatic propagation classical complement pathway thereby preventing formation effectiveness sutimlimab assessed study adults cold agglutinin disease blood transfusion within past six participants received sutimlimab six months could choose continue therapy second part based body weight participants received either g g infusion sutimlimab vein day day every days week total participants responded response defined study increase hemoglobin indirect measurement amount red blood cells destroyed gdl greater gdl greater red blood cell transfusions first five weeks treatment therapies cold agglutinin disease defined us food drug administration fda granted application sutimlimab orphan breakthrough priority review september committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product enjaymo intended treatment hemolytic anemia adults cold agglutinin disease applicant medicinal product genzyme europe sutimlimab approved medical use european union november sutimlimab international nonproprietary name immune activation dostarlimab ibalizumab httpsenwikipediaorgwikisutimlimab